Alzheimer’s Disease Vaccine Candidate Selected for Further Development

AC Immune SA today announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate, has been selected for further development.

The selection of ACI-35.030 is supported by new clinical data from the Phase 1b/2a trial presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2022.

The results show that ACI-35.030 treatment rapidly leads to the strong and durable induction of antibodies specific for pathological forms of Tau, such as pTau and its aggregated form, ePHF.

The ACI-35.030-induced antibody response was sustained and could be periodically boosted over 72 weeks.

And the vaccine candidate was generally well tolerated.

The decision to select ACI-35.030 follows the comparison presented at CTAD, demonstrating its strengths relative to a protein conjugate vaccine, JACI-35.054, an alternative anti-pTau vaccine also being evaluated in parallel in the Phase 1b/2 trial.

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented in a press release on November 30, 2022, "The selection of ACI-35.030 for further development is a significant step for this collaboration."

"Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer's disease (AD)."

"The excellent performance of ACI-35.030 in the trial participants (average age approximately 65 years) potentially opens promising avenues for AD treatment and prevention, which could offer an important societal impact."

The ACI-35.030 anti-pTau vaccine candidate is being developed in collaboration with Janssen Pharmaceuticals, Inc.

Other Alzheimer's disease vaccine and antibody candidates are posted at PrecisionVaccinations.com/Alzheimers.